Cargando…

Safety, efficacy and glucose turnover of reduced prandial boluses during closed‐loop therapy in adolescents with type 1 diabetes: a randomized clinical trial

AIMS: To evaluate safety, efficacy and glucose turnover during closed‐loop with meal announcement using reduced prandial insulin boluses in adolescents with type 1 diabetes (T1D). METHODS: We conducted a randomized crossover study comparing closed‐loop therapy with standard prandial insulin boluses...

Descripción completa

Detalles Bibliográficos
Autores principales: Elleri, D., Biagioni, M., Allen, J. M., Kumareswaran, K., Leelarathna, L., Caldwell, K., Nodale, M., Wilinska, M. E., Haidar, A., Calhoun, P., Kollman, C., Jackson, N. C., Umpleby, A. M., Acerini, C. L., Dunger, D. B., Hovorka, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832358/
https://www.ncbi.nlm.nih.gov/pubmed/26257323
http://dx.doi.org/10.1111/dom.12549
_version_ 1782427242726424576
author Elleri, D.
Biagioni, M.
Allen, J. M.
Kumareswaran, K.
Leelarathna, L.
Caldwell, K.
Nodale, M.
Wilinska, M. E.
Haidar, A.
Calhoun, P.
Kollman, C.
Jackson, N. C.
Umpleby, A. M.
Acerini, C. L.
Dunger, D. B.
Hovorka, R.
author_facet Elleri, D.
Biagioni, M.
Allen, J. M.
Kumareswaran, K.
Leelarathna, L.
Caldwell, K.
Nodale, M.
Wilinska, M. E.
Haidar, A.
Calhoun, P.
Kollman, C.
Jackson, N. C.
Umpleby, A. M.
Acerini, C. L.
Dunger, D. B.
Hovorka, R.
author_sort Elleri, D.
collection PubMed
description AIMS: To evaluate safety, efficacy and glucose turnover during closed‐loop with meal announcement using reduced prandial insulin boluses in adolescents with type 1 diabetes (T1D). METHODS: We conducted a randomized crossover study comparing closed‐loop therapy with standard prandial insulin boluses versus closed‐loop therapy with prandial boluses reduced by 25%. Eight adolescents with T1D [3 males; mean (standard deviation) age 15.9 (1.5) years, glycated haemoglobin 74 (17) mmol/mol; median (interquartile range) total daily dose 0.9 (0.7, 1.1) IU/kg/day] were studied on two 36‐h‐long visits. In random order, subjects received closed‐loop therapy with either standard or reduced insulin boluses administered with main meals (50–80 g carbohydrates) but not with snacks (15–30 g carbohydrates). Stable‐label tracer dilution methodology measured total glucose appearance (Ra_total) and glucose disposal (Rd). RESULTS: The median (interquartile range) time spent in target (3.9–10 mmol/l) was similar between the two interventions [74 (66, 84)% vs 80 (65, 96)%; p = 0.87] as was time spent above 10 mmol/l [21.8 (16.3, 33.5)% vs 18.0 (4.1, 34.2)%; p = 0.87] and below 3.9 mmol/l [0 (0, 1.5)% vs 0 (0, 1.8)%; p = 0.88]. Mean plasma glucose was identical during the two interventions [8.4 (0.9) mmol/l; p = 0.98]. Hypoglycaemia occurred once 1.5 h post‐meal during closed‐loop therapy with standard bolus. Overall insulin delivery was lower with reduced prandial boluses [61.9 (55.2, 75.0) vs 72.5 (63.6, 80.3) IU; p = 0.01] and resulted in lower mean plasma insulin concentration [186 (171, 260) vs 252 (198, 336) pmol/l; p = 0.002]. Lower plasma insulin was also documented overnight [160 (136, 192) vs 191 (133, 252) pmol/l; p = 0.01, pooled nights]. Ra_total was similar [26.3 (21.9, 28.0) vs 25.4 (21.0, 29.2) µmol/kg/min; p = 0.19] during the two interventions as was Rd [25.8 (21.0, 26.9) vs 25.2 (21.2, 28.8) µmol/kg/min; p = 0.46]. CONCLUSIONS: A 25% reduction in prandial boluses during closed‐loop therapy maintains similar glucose control in adolescents with T1D whilst lowering overall plasma insulin levels. It remains unclear whether closed‐loop therapy with a 25% reduction in prandial boluses would prevent postprandial hypoglycaemia.
format Online
Article
Text
id pubmed-4832358
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-48323582016-04-20 Safety, efficacy and glucose turnover of reduced prandial boluses during closed‐loop therapy in adolescents with type 1 diabetes: a randomized clinical trial Elleri, D. Biagioni, M. Allen, J. M. Kumareswaran, K. Leelarathna, L. Caldwell, K. Nodale, M. Wilinska, M. E. Haidar, A. Calhoun, P. Kollman, C. Jackson, N. C. Umpleby, A. M. Acerini, C. L. Dunger, D. B. Hovorka, R. Diabetes Obes Metab Original Articles AIMS: To evaluate safety, efficacy and glucose turnover during closed‐loop with meal announcement using reduced prandial insulin boluses in adolescents with type 1 diabetes (T1D). METHODS: We conducted a randomized crossover study comparing closed‐loop therapy with standard prandial insulin boluses versus closed‐loop therapy with prandial boluses reduced by 25%. Eight adolescents with T1D [3 males; mean (standard deviation) age 15.9 (1.5) years, glycated haemoglobin 74 (17) mmol/mol; median (interquartile range) total daily dose 0.9 (0.7, 1.1) IU/kg/day] were studied on two 36‐h‐long visits. In random order, subjects received closed‐loop therapy with either standard or reduced insulin boluses administered with main meals (50–80 g carbohydrates) but not with snacks (15–30 g carbohydrates). Stable‐label tracer dilution methodology measured total glucose appearance (Ra_total) and glucose disposal (Rd). RESULTS: The median (interquartile range) time spent in target (3.9–10 mmol/l) was similar between the two interventions [74 (66, 84)% vs 80 (65, 96)%; p = 0.87] as was time spent above 10 mmol/l [21.8 (16.3, 33.5)% vs 18.0 (4.1, 34.2)%; p = 0.87] and below 3.9 mmol/l [0 (0, 1.5)% vs 0 (0, 1.8)%; p = 0.88]. Mean plasma glucose was identical during the two interventions [8.4 (0.9) mmol/l; p = 0.98]. Hypoglycaemia occurred once 1.5 h post‐meal during closed‐loop therapy with standard bolus. Overall insulin delivery was lower with reduced prandial boluses [61.9 (55.2, 75.0) vs 72.5 (63.6, 80.3) IU; p = 0.01] and resulted in lower mean plasma insulin concentration [186 (171, 260) vs 252 (198, 336) pmol/l; p = 0.002]. Lower plasma insulin was also documented overnight [160 (136, 192) vs 191 (133, 252) pmol/l; p = 0.01, pooled nights]. Ra_total was similar [26.3 (21.9, 28.0) vs 25.4 (21.0, 29.2) µmol/kg/min; p = 0.19] during the two interventions as was Rd [25.8 (21.0, 26.9) vs 25.2 (21.2, 28.8) µmol/kg/min; p = 0.46]. CONCLUSIONS: A 25% reduction in prandial boluses during closed‐loop therapy maintains similar glucose control in adolescents with T1D whilst lowering overall plasma insulin levels. It remains unclear whether closed‐loop therapy with a 25% reduction in prandial boluses would prevent postprandial hypoglycaemia. Blackwell Publishing Ltd 2015-10-09 2015-12 /pmc/articles/PMC4832358/ /pubmed/26257323 http://dx.doi.org/10.1111/dom.12549 Text en © 2015 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Elleri, D.
Biagioni, M.
Allen, J. M.
Kumareswaran, K.
Leelarathna, L.
Caldwell, K.
Nodale, M.
Wilinska, M. E.
Haidar, A.
Calhoun, P.
Kollman, C.
Jackson, N. C.
Umpleby, A. M.
Acerini, C. L.
Dunger, D. B.
Hovorka, R.
Safety, efficacy and glucose turnover of reduced prandial boluses during closed‐loop therapy in adolescents with type 1 diabetes: a randomized clinical trial
title Safety, efficacy and glucose turnover of reduced prandial boluses during closed‐loop therapy in adolescents with type 1 diabetes: a randomized clinical trial
title_full Safety, efficacy and glucose turnover of reduced prandial boluses during closed‐loop therapy in adolescents with type 1 diabetes: a randomized clinical trial
title_fullStr Safety, efficacy and glucose turnover of reduced prandial boluses during closed‐loop therapy in adolescents with type 1 diabetes: a randomized clinical trial
title_full_unstemmed Safety, efficacy and glucose turnover of reduced prandial boluses during closed‐loop therapy in adolescents with type 1 diabetes: a randomized clinical trial
title_short Safety, efficacy and glucose turnover of reduced prandial boluses during closed‐loop therapy in adolescents with type 1 diabetes: a randomized clinical trial
title_sort safety, efficacy and glucose turnover of reduced prandial boluses during closed‐loop therapy in adolescents with type 1 diabetes: a randomized clinical trial
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832358/
https://www.ncbi.nlm.nih.gov/pubmed/26257323
http://dx.doi.org/10.1111/dom.12549
work_keys_str_mv AT ellerid safetyefficacyandglucoseturnoverofreducedprandialbolusesduringclosedlooptherapyinadolescentswithtype1diabetesarandomizedclinicaltrial
AT biagionim safetyefficacyandglucoseturnoverofreducedprandialbolusesduringclosedlooptherapyinadolescentswithtype1diabetesarandomizedclinicaltrial
AT allenjm safetyefficacyandglucoseturnoverofreducedprandialbolusesduringclosedlooptherapyinadolescentswithtype1diabetesarandomizedclinicaltrial
AT kumareswarank safetyefficacyandglucoseturnoverofreducedprandialbolusesduringclosedlooptherapyinadolescentswithtype1diabetesarandomizedclinicaltrial
AT leelarathnal safetyefficacyandglucoseturnoverofreducedprandialbolusesduringclosedlooptherapyinadolescentswithtype1diabetesarandomizedclinicaltrial
AT caldwellk safetyefficacyandglucoseturnoverofreducedprandialbolusesduringclosedlooptherapyinadolescentswithtype1diabetesarandomizedclinicaltrial
AT nodalem safetyefficacyandglucoseturnoverofreducedprandialbolusesduringclosedlooptherapyinadolescentswithtype1diabetesarandomizedclinicaltrial
AT wilinskame safetyefficacyandglucoseturnoverofreducedprandialbolusesduringclosedlooptherapyinadolescentswithtype1diabetesarandomizedclinicaltrial
AT haidara safetyefficacyandglucoseturnoverofreducedprandialbolusesduringclosedlooptherapyinadolescentswithtype1diabetesarandomizedclinicaltrial
AT calhounp safetyefficacyandglucoseturnoverofreducedprandialbolusesduringclosedlooptherapyinadolescentswithtype1diabetesarandomizedclinicaltrial
AT kollmanc safetyefficacyandglucoseturnoverofreducedprandialbolusesduringclosedlooptherapyinadolescentswithtype1diabetesarandomizedclinicaltrial
AT jacksonnc safetyefficacyandglucoseturnoverofreducedprandialbolusesduringclosedlooptherapyinadolescentswithtype1diabetesarandomizedclinicaltrial
AT umplebyam safetyefficacyandglucoseturnoverofreducedprandialbolusesduringclosedlooptherapyinadolescentswithtype1diabetesarandomizedclinicaltrial
AT acerinicl safetyefficacyandglucoseturnoverofreducedprandialbolusesduringclosedlooptherapyinadolescentswithtype1diabetesarandomizedclinicaltrial
AT dungerdb safetyefficacyandglucoseturnoverofreducedprandialbolusesduringclosedlooptherapyinadolescentswithtype1diabetesarandomizedclinicaltrial
AT hovorkar safetyefficacyandglucoseturnoverofreducedprandialbolusesduringclosedlooptherapyinadolescentswithtype1diabetesarandomizedclinicaltrial